Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Javier Cortés, Sara A. Hurvitz, Seock‐Ah Im, et al.
Nature Medicine (2024) Vol. 30, Iss. 8, pp. 2208-2215
Open Access | Times Cited: 21

Showing 21 citing articles:

Adverse events and impact on quality of life of antibody‐drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta‐analysis
Marta Perachino, Eva Blondeaux, Chiara Molinelli, et al.
European Journal of Clinical Investigation (2025)
Open Access | Times Cited: 1
Current and future immunotherapy for breast cancer
Natalie K. Heater, Surbhi Warrior, Janice Lu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 5
Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing
Tess A. O’Meara, Paolo Tarantino, Stefania Morganti, et al.
Current Oncology Reports (2025)
Closed Access
A Dramatic Clinical Response to Trastuzumab-Deruxtecan in a Patient with HER-2 Low Breast Cancer with Untreated Leptomeningeal Metastasis and Hydrocephalus
Sarah Hussain, Robert Nordal, Danny Siu‐Chun Ng, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 81-81
Open Access
Full-length transcriptome atlas of gallbladder cancer reveals trastuzumab resistance conferred by ERBB2 alternative splicing
Ziyi Wang, Li Gao, Ziheng Jia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer
Xichun Hu, Qingyuan Zhang, Leiping Wang, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Antibody-Drug conjugates In elderly patients With Breast Cancer
Marta Bonotto, G Pieri, Rocco Esposto, et al.
The Breast (2025) Vol. 80, pp. 104428-104428
Open Access
Highlights of 2024. Broadening anti‐cancer immunotherapy modalities with antibody–drug conjugates: emerging insights from clinical studies
Jiya Jose, John D. Hooper, Fernando Souza-Fonseca-Guimarães
Immunology and Cell Biology (2025)
Closed Access
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
Li-Chung Tsao, John S. Wang, Xingru Ma, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
ADCs beim metastasierten Mammakarzinom
Katharina Kaschner, Achim Rody, Maggie Banys‐Paluchowski
Die Gynäkologie (2025)
Closed Access
The Ideal Strategies of Antibody‒Drug Conjugate Sequential Treatment in HER2-expressing Metastatic Breast Cancer: A Multi-Center Real-World Study
Xuenan Peng, Bo Lan, Jiayu Wang, et al.
The Breast (2025), pp. 104470-104470
Open Access
Genetic factors in the pathogenesis of cardio-oncology
Yalong Qi, Yuhan Wei, Lixi Li, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Updates in Treatment of HER2-positive Metastatic Breast Cancer
A. Avelino, Soumya Pulipati, Kevin Tony Jamouss, et al.
Current Treatment Options in Oncology (2024)
Closed Access | Times Cited: 2
Choice of therapy for HER2-positive metastatic breast cancer in real clinical practice: analysis of physician preferences in Russian Federation
Е. В. Артамонова, E. V. Lubennikova
Medical alphabet (2024), Iss. 27, pp. 60-66
Closed Access | Times Cited: 1
History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region
Antonella Giorgia Becchetti, Anna M. Martini, Giovanna Scroccaro, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Development of graded prognostic assessment for breast Cancer brain metastasis incorporating extracranial metastatic features: a retrospective analysis of 284 patients
Yan Wang, Hangcheng Xu, Qiang Sa, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting
Mita Manna, Karen A. Gelmon, Jean-François Boileau, et al.
Current Oncology (2024) Vol. 31, Iss. 11, pp. 6536-6567
Open Access
Enhanced Tumor Penetration of HER2-Targeting Nanodrugs by Vascular Disrupting Agent
Xiaodong Wang, Ying Song, Ruifeng Duan, et al.
ACS Applied Nano Materials (2024)
Closed Access
Current Evidence in the Systemic Treatment of Brain Metastases from Breast Cancer and Future Perspectives on New Drugs, Combinations and Administration Routes: A Narrative Review
Ornella Garrone, Fiorella Ruatta, Carmen G. Rea, et al.
Cancers (2024) Vol. 16, Iss. 24, pp. 4164-4164
Open Access
Quality-adjusted time without symptoms or toxicity analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial
Natalie Dennis, K. Dunton, C. Livings, et al.
European Journal of Cancer (2024) Vol. 217, pp. 115192-115192
Open Access
Rewiring oncogenic signaling to RNA vector replication for the treatment of metastatic cancer
Xinzhi Zou, Chao Zhao, Kevin T. Beier, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
Page 1

Scroll to top